| Number unique A-genes | 1 |
|---|---|
| Number unique B-genes | 6 |
| Number unique A-B gene pairs | 6 |
| Total number of interactions | 1305 |
| A-argument | B-argument | count |
|---|---|---|
| MTOR | AMPK | 1176 |
| MTOR | PRKAA2 | 59 |
| MTOR | PRKAA1 | 51 |
| MTOR | PRKAB1 | 16 |
| MTOR | PRKAB2 | 2 |
| MTOR | PRKAG1 | 1 |
| input | recognized symbol | mapping type |
|---|---|---|
| mtor | MTOR | Orthology Cluster |
| input | recognized symbol | mapping type |
|---|---|---|
| ampk | AMPK | FamPlex Concept |
| input | recognized symbol | mapping type |
|---|---|---|
| mtor | MTOR | Orthology Cluster |
| input | recognized symbol | mapping type |
|---|---|---|
| ampk | AMPK | FamPlex Concept |
| Gene A Symbol | Gene B Symbol | Gene A Gene ID | Gene B Gene ID | Relation Types | Factuality | Fulltext Match Source | Document ID | Context |
|---|---|---|---|---|---|---|---|---|
| MTOR | PRKAA2 | 2475 | 5563 | Regulation | none | 19679549 | Metformin, the most widely used drug in the treatment of type 2 diabetes, activates AMP kinase (AMPK), which negatively regulates mTOR. | |
| MTOR | AMPK | 2475 | FPLX:AMPK | Regulation | none | 19679549 | Metformin, the most widely used drug in the treatment of type 2 diabetes, activates AMP kinase (AMPK), which negatively regulates mTOR. | |
| MTOR | PRKAA1 | 2475 | 5562 | Negative_regulation, Positive_regulation | none | 25591762 | High glucose-induced extracellular matrix accumulation and mTOR activation were significantly inhibited by the co-treatment of rAAV-AMPKα1(312) (encoding constitutively active AMPKα1) whereas activated by r-AAV-AMPKα1D157A (encoding dominant negative AMPKα1). | |
| MTOR | AMPK | 2475 | FPLX:AMPK | Regulation | none | 33714781 | Besides, metformin inhibits cystic fibrosis transmembrane conductance regulator (CFTR)-mediated fluids secretion and the mammalian target of rapamycin (mTOR)-involved cyst formation negatively regulated by AMPK in autosomal dominant polycystic kidney disease (APDKD). | |
| MTOR | AMPK | 2475 | FPLX:AMPK | Negative_regulation | none | 32245619 | Humanin attenuates palmitate-induced hepatic lipid accumulation and insulin resistance via AMPK-mediated suppression of the mTOR pathway. | |
| MTOR | AMPK | 2475 | FPLX:AMPK | Regulation | none | PMC4880882 | Metformin has been shown to alter AMPK, a protein kinase that directly and indirectly regulates mTOR signaling via phosphorylation of Raptor and TSC2, respectively. | |
| MTOR | AMPK | 2475 | FPLX:AMPK | Positive_regulation | none | PMC8945547 | In hypopharyngeal cancer cells, p-mTOR was reduced through activation of ERK and AMPK signaling pathways by metformin, resulting in cell cycle arrest, apoptosis and autophagy triggering []. | |
| MTOR | AMPK | 2475 | FPLX:AMPK | Positive_regulation | none | PMC5386770 | Interestingly, Jin et al. proposed that Twist1 depletion sensitized NSCLC cells to cisplatin by stimulating AMPK-induced mTOR inhibition and subsequent reduction in Mcl-1 protein []. | |
| Mtor | AMPK | 56718 | FPLX:AMPK | Regulation | none | PMC9526660 | In addition, the mTOR is negatively regulated by AMPK, of which expression is up-regulated with suppressed autophagy. | |
| MTOR | AMPK | 2475 | FPLX:AMPK | Negative_regulation, Positive_regulation | none | PMC6690605 | Moreover, it also enhanced the lumican expression transcriptionally, which indicated that hypoxia-induced mTOR activation was blocked by activated AMPK. |
Interaction data is being assembled. This may take a while depending on result size and server load. You can use the link below to fetch the download at a later time. The link is valid at least 24h.